Individuals with solar lentigines on forearm Skin: Does twice daily application of a topical formulation with a new inhibitor of human tyrosinase reduce skin hyperpigmentation?

Beiersdorf AG0 个研究点目标入组 20 人开始时间: 2018年1月25日最近更新: 2018年2月19日

试验速览

暂无简介。

•1. Females/ males between 50 and 70 years of age in generally good health
•2. Solar Lentigines on the arms but otherwise healthy, undamaged skin in the test sites
•3. Fitzpatrick skin phototype I, II, III or IV
•4. Ability to understand the study concept (intellectual capacity and language skills) and to comply with the test schedule and study rules
•5. Participant is willing and able to give written informed consent

•1. Active, acute skin ailments in the test sites, for example atopic Dermatitis or eczema
•2. Changes to the skin which conflict with study goals
•3. Systemic or topical medication which counteract study objectives
•4. Medications, taken either orally or applied topically within the last 4 weeks, which impair immune reactions, for example cytostatic agents and cortisone
•5. Severe general illness, either currently or within the last 12 months, for example malignant tumor, severe diabetes, severe cardiovascular disease (e.g. cerebral apoplexy, myocardial infarction, bypass or decompensated high blood pressure)

发起方